Skip to Content
Merck
CN

Key Documents

View All Documentation

SML1133

SGC-CBP30

≥98% (HPLC)

Synonym(s):

2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(S)-2-(morpholin-4-yl)propyl]-1H-benzimidazole

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C28H33ClN4O3
CAS Number:
1613695-14-9
Molecular Weight:
509.04
UNSPSC Code:
51111800
PubChem Substance ID:
329825669
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

2-8°C

SMILES string

CC1=C(C(C)=NO1)C2=CC=C3C(N=C(CCC4=CC=C(OC)C(Cl)=C4)N3C[C@@H](N5CCOCC5)C)=C2

InChI

1S/C28H33ClN4O3/c1-18(32-11-13-35-14-12-32)17-33-25-8-7-22(28-19(2)31-36-20(28)3)16-24(25)30-27(33)10-6-21-5-9-26(34-4)23(29)15-21/h5,7-9,15-16,18H,6,10-14,17H2,1-4H3/t18-/m0/s1

InChI key

GEPYBHCJBORHCE-SFHVURJKSA-N

Related Categories

Application

SGC-CBP30 has been used in immunofluorescence, to study the regulation of HAT (histone acetyltransferase) activity. It has also been used to abolish synergistic gene expression induced by transcription factors in hepatocytes.

Biochem/physiol Actions

SGC-CBP30 might serve as a therapeutic agent in treating cancer. In ankylosing spondylitis and psoriatic arthritis condition, SGC-CBP30 is found to decrease immune cell production of T helper cell 17 and other pro-inflammatory cytokines.
SGC-CBP30 is a selective inhibitor of the bromodomain-containing transcription factors CREBBP (CBP) and EP300 (IC50 = 0.021 and 0.038 μM, respectively). SGC-CBP30 has little activity against other bromodomains at concentrations up to 1 mM. For full characterization details, please visit the SGC-CBP30 probe summary on the Structural Genomics Consortium (SGC) website.

To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc
SGC-CBP30 is a selective inhibitor of the bromodomain-containing transcription factors CREBBP (CBP) and EP300.

Features and Benefits

SGC-CBP30 is an epigenetic chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC epigenetic probes, visit sigma.com/SGC.
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Other Notes

SGC-CBP30 has been expertly reviewed and recommended by the Chemical Probes Portal. For more information, please visit the SGC-CBP30 probe summary on the Chemical Probes Portal website.

hcodes

H413

Hazard Classifications

Aquatic Chronic 4

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000219413
0000219413
0000173884
0000165489
0000173884

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Clinical progress and pharmacology of small molecule bromodomain inhibitors
Theodoulou NH, et al.
Current Opinion in Chemical Biology, 33, 58-66 (2016)
Transcription factor dimerization activates the p300 acetyltransferase
Ortega E, et al.
Nature, 1-1 (2018)
Epigenetic Targets in Drug Discovery, 144-144 (2018)
Synergistic gene expression during the acute phase response is characterized by transcription factor assisted loading.
Goldstein I, et al.
Nature Communications, 8(1), 1849-1849 (2017)
Irena Hlushchuk et al.
ACS chemical neuroscience, 12(13), 2273-2279 (2021-06-11)
Neurodegenerative diseases are associated with failed proteostasis and accumulation of insoluble protein aggregates that compromise neuronal function and survival. In Parkinson's disease, a major pathological finding is Lewy bodies and neurites that are mainly composed of phosphorylated and aggregated α-synuclein
View All Related Papers

Articles

Discover Bioactive Small Molecules for Gene Regulation

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

Global Trade Item Number

SKUGTIN
SML1133-5MG04061832825304
SML1133-25MG04061832825298

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service